Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)

Journal of the American Academy of Dermatology(2020)10.1016/j.jaad.2020.09.047Source: DataRank Database

Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2) is a research paper published in Journal of the American Academy of Dermatology (2020). On theSindex it has a DataRank of 0. It has been cited 27 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

27 citations

Free full text

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (21 grants)Impact (FWCI 0.86)OA: hybridTopics (45)IDs (PubMed, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Craig L. Leonardi,Nehal N. Mehta ORCID,Alice B. Gottlieb ORCID,Alan M. Mendelsohn,Jeff Parno

Live enrichment

PubMed:32961255 OpenAlex:https://openalex.org/W3087357472

National Institutes of Health

Dermavant

Janssen

LEO Pharma

AbbVie

Arcutis

Eli Lilly

Janssen Research & Development

LLC

Boehringer Ingelheim

Celgene

Novartis

Incyte

Pfizer

UCB

XBiotech

Amgen

Merck

Merck Sharp and Dohme

Ortho Dermatologics

Sun Pharmaceutical Industries Ltd.

FWCI

0.86

Citation Percentile

0.7%

Citation Trend

2021

2022

2023

2024

2025

2026

hybridLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.jaad.2020.09.047

publisherhttps://doi.org/10.1016/j.jaad.2020.09.047

publisherhttps://api.elsevier.com/content/article/PII:S0190962220326372?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0190962220326372?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/32961255

Fields of Study

Psoriasis: Treatment and PathogenesisSpondyloarthritis Studies and TreatmentsSkin Diseases and DiabetesAdultAntibodies, Monoclonal, HumanizedComorbidityDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansMaleMetabolic SyndromeMiddle AgedPsoriasisSeverity of Illness IndexTime FactorsTreatment Outcome

MeSH Terms

AdultDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansMaleMiddle AgedPsoriasisSeverity of Illness IndexTime FactorsComorbidityTreatment OutcomeMetabolic SyndromeAntibodies, Monoclonal, Humanized

Keywords

MedicinePsoriasisInternal medicinePsoriasis Area and Severity IndexPost-hoc analysisMetabolic syndromeAdverse effectDermatologyObesitySafetyClinical researchefficacyInterleukin 23Tildrakizumab

Sustainable Development Goals

SDG 0: Good health and well-being

Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)

FAIR Checklist

Authors (8)

Funding (21 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)